235
Views
13
CrossRef citations to date
0
Altmetric
Hematological Malignancy: Current Clinical Practice: Review

Lenalidomide: a synthetic compound with an evolving role in cancer management

&
Pages 318-331 | Published online: 29 Nov 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Tomer M. Mark, Isaac A. Bowman, Adriana C. Rossi, Manan Shah, Melissa Rodriguez, Ryann Quinn, Roger N. Pearse, Faiza Zafar, Karen Pekle, David Jayabalan, Scott Ely, Morton Coleman, Selina Chen-Kiang & Ruben Niesvizky. (2014) Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. Leukemia & Lymphoma 55:12, pages 2842-2849.
Read now

Articles from other publishers (12)

Ruili Liang, Yitong Zhu, Yanyang Wu, Xing Gu & Xiangyang Zhang. (2022) The role of phosphoric acid in the crystallization of lenalidomide form DH–water system. CrystEngComm 24:36, pages 6357-6366.
Crossref
Ang Li, Zehao Si, Yizhen Yan & Xiangyang Zhang. (2021) Solubility and thermodynamic properties of hydrate lenalidomide in phosphoric acid solution. Journal of Molecular Liquids 330, pages 115446.
Crossref
Celia Arib & Jolanda Spadavecchia. (2020) Lenalidomide (LENA) Hybrid Gold Complex Nanoparticles: Synthesis, Physicochemical Evaluation, and Perspectives in Nanomedicine. ACS Omega 5:44, pages 28483-28492.
Crossref
Rongrong Li, Longcai Liu, Arshad Khan, Chenghong Li, Zhicai He, Jia Zhao & Deman Han. (2019) Effect of Cosolvents on the Solubility of Lenalidomide and Thermodynamic Model Correlation of Data. Journal of Chemical & Engineering Data 64:10, pages 4272-4279.
Crossref
Monika Anna Grygorowicz, Ilona Sara Borycka, Eliza Nowak, Ewa Paszkiewicz-Kozik, Grzegorz Rymkiewicz, Katarzyna Błachnio, Marzena Biernacka, Mateusz Bujko, Jan Walewski & Sergiusz Markowicz. (2016) Lenalidomide potentiates CD4+CD25+Treg-related suppression of lymphoma B-cell proliferation. Clinical and Experimental Medicine 17:2, pages 193-207.
Crossref
Emmanouil Nikolousis. 2014. Horizons in Clinical Nanomedicine. Horizons in Clinical Nanomedicine 93 113 .
Josep Ordi-Ros & Francisco Javier Cosiglio. (2014) Indicaciones terapéuticas actuales de la talidomida y la lenalidomida. Medicina Clínica 142:8, pages 360-364.
Crossref
Katja Weisel & Lothar Kanz. 2014. Small Molecules in Oncology. Small Molecules in Oncology 347 357 .
Isabel Bielsa Marsol. (2013) Indicaciones de talidomida y sus derivados en dermatología. Piel 28:10, pages 606-613.
Crossref
Vu H. Duong, Rami S. Komrokji & Alan F. List. (2012) Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion. Therapeutic Advances in Hematology 3:2, pages 105-116.
Crossref
Jessica M. McDaniel, Javier Pinilla-Ibarz & P. K. Epling-Burnette. (2012) Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies. Advances in Hematology 2012, pages 1-9.
Crossref
Bang‐Ning Lee, Hui Gao, Evan N. Cohen, Xavier Badoux, William G. Wierda, Zeev Estrov, Stefan H. Faderl, Michael J. Keating, Alessandra Ferrajoli & James M. Reuben. (2011) Treatment with lenalidomide modulates T‐cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer 117:17, pages 3999-4008.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.